Three-Drug attack on tough stomach cancers
NCT ID NCT07309185
Summary
This study is for people with advanced stomach cancer that has gotten worse after their first treatment. It will test if adding two new drugs (adebrelimab and famitinib) to a standard chemotherapy drug (irinotecan) works better and is safe compared to using the chemotherapy drug alone. About 66 participants will be randomly assigned to receive either the three-drug combination or just the single chemotherapy drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STOMACH NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong First Medical University Affiliated Cancer Hospital
RECRUITINGJinan, Shandong, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.